Lyra TherapeuticsInc Net Worth
Lyra TherapeuticsInc Net Worth Breakdown | LYRA |
Lyra TherapeuticsInc Net Worth Analysis
Lyra TherapeuticsInc's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lyra TherapeuticsInc's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lyra TherapeuticsInc's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lyra TherapeuticsInc's net worth analysis. One common approach is to calculate Lyra TherapeuticsInc's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lyra TherapeuticsInc's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lyra TherapeuticsInc's net worth. This approach calculates the present value of Lyra TherapeuticsInc's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lyra TherapeuticsInc's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lyra TherapeuticsInc's net worth. This involves comparing Lyra TherapeuticsInc's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lyra TherapeuticsInc's net worth relative to its peers.
Enterprise Value |
|
To determine if Lyra TherapeuticsInc is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lyra TherapeuticsInc's net worth research are outlined below:
| Lyra TherapeuticsInc generated a negative expected return over the last 90 days | |
| Lyra TherapeuticsInc has high historical volatility and very poor performance | |
| Lyra TherapeuticsInc has some characteristics of a very speculative penny stock | |
| Lyra TherapeuticsInc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.56 M. Net Loss for the year was (62.68 M) with loss before overhead, payroll, taxes, and interest of (34.23 M). | |
| Lyra TherapeuticsInc currently holds about 120.67 M in cash with (63.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Analysts Set Lyra Therapeutics, Inc. PT at 7.13 - Defense World |
Lyra TherapeuticsInc uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lyra TherapeuticsInc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lyra TherapeuticsInc's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lyra TherapeuticsInc's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyra TherapeuticsInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyra TherapeuticsInc backward and forwards among themselves. Lyra TherapeuticsInc's institutional investor refers to the entity that pools money to purchase Lyra TherapeuticsInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parkman Healthcare Partners Llc | 2023-12-31 | 754.9 K | Woodline Partners Lp | 2023-12-31 | 600 K | Geode Capital Management, Llc | 2023-12-31 | 336.5 K | Millennium Management Llc | 2023-12-31 | 326 K | Ensign Peak Advisors Inc | 2023-12-31 | 301.5 K | Susquehanna International Group, Llp | 2023-12-31 | 259.4 K | Boothbay Fund Management, Llc | 2023-12-31 | 249.9 K | Bank Of America Corp | 2023-12-31 | 144.7 K | Bridgeway Capital Management, Llc | 2023-12-31 | 141.8 K | Perceptive Advisors Llc | 2023-12-31 | 12.8 M | Nantahala Capital Management, Llc | 2023-12-31 | 8.1 M |
Follow Lyra TherapeuticsInc's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.69 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lyra TherapeuticsInc's market, we take the total number of its shares issued and multiply it by Lyra TherapeuticsInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Project Lyra TherapeuticsInc's profitablity
Lyra TherapeuticsInc's profitability indicators refer to fundamental financial ratios that showcase Lyra TherapeuticsInc's ability to generate income relative to its revenue or operating costs. If, let's say, Lyra TherapeuticsInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Lyra TherapeuticsInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Lyra TherapeuticsInc's profitability requires more research than a typical breakdown of Lyra TherapeuticsInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.70) | (0.74) |
When accessing Lyra TherapeuticsInc's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lyra TherapeuticsInc's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lyra TherapeuticsInc's profitability and make more informed investment decisions.
The data published in Lyra TherapeuticsInc's official financial statements usually reflect Lyra TherapeuticsInc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lyra TherapeuticsInc. For example, before you start analyzing numbers published by Lyra accountants, it's critical to develop an understanding of what Lyra TherapeuticsInc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lyra TherapeuticsInc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lyra TherapeuticsInc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lyra TherapeuticsInc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lyra TherapeuticsInc. Please utilize our Beneish M Score to check the likelihood of Lyra TherapeuticsInc's management manipulating its earnings.
Evaluate Lyra TherapeuticsInc's management efficiency
Lyra TherapeuticsInc has return on total asset (ROA) of (0.381) % which means that it has lost $0.381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9593) %, meaning that it created substantial loss on money invested by shareholders. Lyra TherapeuticsInc's management efficiency ratios could be used to measure how well Lyra TherapeuticsInc manages its routine affairs as well as how well it operates its assets and liabilities. As of May 17, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.56. At present, Lyra TherapeuticsInc's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 39.7 M, whereas Total Assets are forecasted to decline to about 78.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.80 | 1.89 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.80 | 1.89 | |
| Enterprise Value Over EBITDA | (4.07) | (4.27) | |
| Price Book Value Ratio | 2.92 | 2.77 | |
| Enterprise Value Multiple | (4.07) | (4.27) | |
| Price Fair Value | 2.92 | 2.77 | |
| Enterprise Value | 265.5 M | 278.8 M |
The analysis of Lyra TherapeuticsInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Lyra TherapeuticsInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Lyra Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Enterprise Value Revenue 153.7687 | Revenue 1.7 M | Quarterly Revenue Growth 0.298 | Revenue Per Share 0.03 | Return On Equity (0.96) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyra TherapeuticsInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyra TherapeuticsInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyra TherapeuticsInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyra TherapeuticsInc time-series forecasting models is one of many Lyra TherapeuticsInc's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyra TherapeuticsInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lyra TherapeuticsInc Earnings per Share Projection vs Actual
Be your own money manager
Our tools can tell you how much better you can do entering a position in Lyra TherapeuticsInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Lyra TherapeuticsInc Corporate Management
Elected by the shareholders, the Lyra TherapeuticsInc's board of directors comprises two types of representatives: Lyra TherapeuticsInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lyra. The board's role is to monitor Lyra TherapeuticsInc's management team and ensure that shareholders' interests are well served. Lyra TherapeuticsInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lyra TherapeuticsInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr Roberts | CoFounder | Profile | |
| Corinne Noyes | Senior Development | Profile | |
| Donald MBA | Advisor | Profile | |
| Ellen Cavaleri | Senior Communications | Profile | |
| Richard MD | Chief Officer | Profile | |
| Ronan JD | Chief Officer | Profile | |
| John Bishop | Chief Officer | Profile |
How to buy Lyra Stock?
The net worth of Lyra TherapeuticsInc is the difference between its total assets and liabilities. Lyra TherapeuticsInc's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Lyra TherapeuticsInc's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Lyra TherapeuticsInc's net worth can be used as a measure of its financial health and stability which can help investors to decide if Lyra TherapeuticsInc is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Lyra TherapeuticsInc stock.Already Invested in Lyra TherapeuticsInc?
The danger of trading Lyra TherapeuticsInc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Lyra TherapeuticsInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Lyra TherapeuticsInc. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Lyra TherapeuticsInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Lyra TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeuticsinc Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra TherapeuticsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Lyra Stock analysis
When running Lyra TherapeuticsInc's price analysis, check to measure Lyra TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyra TherapeuticsInc is operating at the current time. Most of Lyra TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Lyra TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyra TherapeuticsInc's price. Additionally, you may evaluate how the addition of Lyra TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Lyra TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra TherapeuticsInc. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.298 | Return On Assets (0.38) | Return On Equity (0.96) |
The market value of Lyra TherapeuticsInc is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Lyra TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra TherapeuticsInc's market value can be influenced by many factors that don't directly affect Lyra TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.